Related Experiment Video
Updated: Sep 14, 2025

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
NNMT inhibition in cancer-associated fibroblasts restores antitumour immunity
Janna Heide1, Agnes J Bilecz1, Samarjit Patnaik2
1Department of Obstetrics and Gynecology, Section of Gynecologic Oncology, University of Chicago, Chicago, IL, USA.
Abstract:
Cancer-associated fibroblasts (CAFs) have a pivotal cancer-supportive role, yet CAF-targeted therapies are lacking1,2. Here, using spatial transcriptomics and single-cell RNA sequencing, we investigate the role of nicotinamide N-methyltransferase (NNMT) in high-grade serous ovarian cancer. Mechanistically, NNMT-induced H3K27me3 hypomethylation drives complement secretion from CAFs, attracting immunosuppressive myeloid-derived suppressor cells (MDSCs) to the tumour. Nnmt knockout in immunocompetent mice impairs tumour growth in syngeneic ovarian, breast and colon tumour models through enhanced CD8+ T cell activation. Using high-throughput screening, we develop a potent and specific NNMT inhibitor that reduces the tumour burden and metastasis in multiple mouse cancer models and restores immune checkpoint blockade efficacy by decreasing CAF-mediated recruitment of MDSCs and reinvigorating CD8+ T cell activation. Our findings establish NNMT as a central CAF regulator and a promising therapeutic target to mitigate immunosuppression in the tumour microenvironment.
Insights
Nicotinamide N-methyltransferase (NNMT) fuels cancer by recruiting immunosuppressive cells. Inhibiting NNMT in cancer-associated fibroblasts (CAFs) boosts anti-tumor immunity and reduces tumor growth, offering a new therapeutic strategy.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Cancer-associated fibroblasts (CAFs) play a critical role in tumor progression.
- Targeting CAFs remains a challenge in cancer therapy.
Purpose of the Study:
- To investigate the role of nicotinamide N-methyltransferase (NNMT) in high-grade serous ovarian cancer.
- To identify NNMT as a potential therapeutic target for cancer treatment.
Main Methods:
- Spatial transcriptomics and single-cell RNA sequencing were employed.
- NNMT's role was assessed in syngeneic mouse models of ovarian, breast, and colon cancer.
- High-throughput screening was used to identify NNMT inhibitors.
Main Results:
- NNMT promotes tumor growth by inducing H3K27me3 hypomethylation in CAFs, leading to the secretion of immunosuppressive factors and recruitment of myeloid-derived suppressor cells (MDSCs).
- NNMT knockout impaired tumor growth and enhanced CD8+ T cell activation in multiple cancer models.
- A novel NNMT inhibitor reduced tumor burden, metastasis, and restored anti-tumor immunity.
Conclusions:
- NNMT is a key regulator of CAFs and immunosuppression within the tumor microenvironment.
- Targeting NNMT represents a promising therapeutic strategy to enhance anti-tumor immunity and overcome treatment resistance.
More Related Videos
Related Concept Videos
The Tumor Microenvironment
Tumor Immunotherapy
Mitogens and the Cell Cycle
Targeted Cancer Therapies
There are several types of targeted therapies against...

